FIGURE 4.

Pharmacological blockade of the ROS-producing enzymes affected AEA-modulated LTP in hippocampus of D-gal-treated rats. (A) Time course of LTP with a 35 min infusion of the NADPH oxidase inhibitor acetovanillone (ACE, 100 μM, i.c.v), or a 20 min ACE infusion followed by a 15 min AEA introhippocampal application (1 μM), or only vehicle treatment prior to HFS in D-gal-treated rats. Right, representative fEPSP traces before (1) and 40 min (2) after HFS. (B,C) Similar to (A), except that a non-selective NOS inhibitor diphenyleneiodonium (DPI, 200 μM, in B) and a selective COX-2 inhibitor NS398 (250 μM, in C) were used for the study, respectively. The vehicle was normal saline solution containing 1% DMSO. It was used in both i.c.v infusions and intrahippocampus microinjections. The fEPSP data in vehicle groups in (A–C) were from the same five rats. (D) Quantification of fEPSP slope change indicated the ROS-producing enzymes conveyed different effects on AEA-modulated LTP. All n = 5. *P < 0.05, **P < 0.01, ***P < 0.001 as determined by one-way ANOVA followed by Bonferroni’s t-test. Calibration: 5 ms, 0.5 mV.